220651-94-5

Basic information

• Product Name: Ruplizumab
• Synonyms: Bg9588;Immunoglobulin G1, (anti-human cd40 ligand)(human-mouse monoclonal 5C8 gamma1-chain), disulfide with human-mouse monoclonal 5C8 kappa-chain, dimer;Ruplizumab
• CAS NO: 220651-94-5
• Mol File: 220651-94-5.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ruplizumab(CAS DataBase Reference)
• NIST Chemistry Reference: Ruplizumab(220651-94-5)
• EPA Substance Registry System: Ruplizumab(220651-94-5)

Safety Data

• Hazardous Substances Data: 220651-94-5(Hazardous Substances Data)

Usage

Description

Ruplizumab, also known as a humanized monoclonal antibody, is a pharmaceutical compound specifically designed to target and neutralize certain immune responses. It is engineered to bind with high specificity to its target, making it a promising candidate for various therapeutic applications.
Source:
Ruplizumab is developed through a process of genetic engineering, where the variable region of a mouse monoclonal antibody is grafted onto a human antibody framework to reduce the risk of immunogenicity.
Production Methods:
The production of Ruplizumab involves the use of recombinant DNA technology, where the desired antibody genes are inserted into a suitable host cell, such as a Chinese hamster ovary (CHO) cell line. These host cells are then cultured and induced to produce the monoclonal antibody.

Uses

Used in Immunology:
Ruplizumab is used as a therapeutic agent for the treatment of immune thrombocytopenic purpura (ITP), a condition characterized by low platelet count and increased bleeding risk. It targets the Fc gamma receptor IIB, modulating the immune response and reducing the destruction of platelets.
Additionally, Ruplizumab is used as a treatment option for systemic lupus erythematosus (SLE), an autoimmune disease that can affect various organs and systems in the body. By targeting the same Fc gamma receptor IIB, it helps to regulate the immune system and alleviate the symptoms associated with SLE.